Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Rang in Aktien
#3422
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Aktienkurs
$4.48
Marktkapitalisierung
$4.99B
Veränderung (1 Tag)
-5.20%
Veränderung (1 Jahr)
-41.89%
Land
CN
Handel Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Kategorie
Healthcare
Umsatz von Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Umsatz im Jun 2026 TTM: $703.92M
Laut den aktuellen Finanzberichten von Shenzhen Salubris Pharmaceuticals Co., Ltd. beträgt der derzeitige Umsatz des Unternehmens (TTM) $703.92M. Im Jahr 2024 erzielte das Unternehmen einen Umsatz von $549.69M eine Steigerung gegenüber dem Umsatz im Jahr 2023, der $475.42M betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Shenzhen Salubris Pharmaceuticals Co., Ltd. von 2006 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $703.92M | 14.35% |
| 2025 | $615.57M | 11.98% |
| 2024 | $549.69M | 15.62% |
| 2023 | $475.42M | -5.82% |
| 2022 | $504.79M | 4.91% |
| 2021 | $481.19M | 14.79% |
| 2020 | $419.21M | -34.70% |
| 2019 | $642.00M | -5.07% |
| 2018 | $676.28M | 5.93% |
| 2017 | $638.43M | 15.63% |
| 2016 | $552.15M | 3.10% |
| 2015 | $535.54M | 15.07% |
| 2014 | $465.40M | 21.29% |
| 2013 | $383.71M | 30.83% |
| 2012 | $293.29M | 25.36% |
| 2011 | $233.95M | 18.99% |
| 2010 | $196.62M | 58.00% |
| 2009 | $124.44M | 61.08% |
| 2008 | $77.26M | 61.43% |
| 2007 | $47.86M | 83.90% |
| 2006 | $26.02M | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $11.58B | 1,544.78% |
US
|
|
| $34.74B | 4,834.71% |
FR
|
|
| $6.22B | 784.09% |
JP
|
|
| $20.84B | 2,860.41% |
US
|
|
| $10.77B | 1,430.66% |
CH
|
